arrow
E

Emanuela Risi

european university cyprus
H指数:18
被引数:1,165

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study

CDK4/6抑制剂剂量模式在老年转移性乳腺癌患者中的分布:一项跨国调查研究

2026-07-010
PRE
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
2024-12-010
PRE
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
2024-10-211
OAAI
Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial

老年科医生实施的干预措施对早期或晚期实体瘤易感老年患者化疗(CT)给药的影响:GIVE试验

2024-09-010
PRE
Sensitive tumor detection, accurate quantification, and ER subtyping using low-pass methylome of liquid biopsy samples from patients (pts) with metastatic breast cancer (mBC)
2024-05-020
PRE
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
2023-03-010
PRE
Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial
2023-03-010
PRE
Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy
2023-03-010
PRE
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

ER阳性,HER2-negative晚期乳腺癌患者的循环肿瘤细胞和palbociclib治疗: TREnd试验的转化子研究结果

2021-03-2418
OAAI
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
2020-08-058
OAAI
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
2020-05-0143
OAAI
Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR plus ) operable breast cancer (BC)
2020-02-150
PRE
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
2019-12-114
OAAI